Etrumadenant · AB-928

What is Etrumadenant?

Etrumadenant is an orally bioavailable antagonist of the adenosine A2A and A2B receptors, which are expressed on intratumoral immune cells such as dendritic cells, NK cells, macrophages and T lymphocytes. By blocking tumor-released adenosine from binding these receptors, it aims to reduce adenosine-mediated immunosuppression. It is studied in metastatic castration-resistant prostate cancer and prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

AB-928

Drug type

Small molecule

Targets

adenosine A2A receptor (ADORA2A), adenosine A2B receptor (ADORA2B)

Mechanism

Antagonist of adenosine A2A receptor (ADORA2A) and adenosine A2B receptor (ADORA2B)

Pathways

adenosine-A2AR/A2BR signaling, adenosine-mediated immunosuppression in the tumor microenvironment

Therapy area

Oncology

Developer

Arcus Biosciences, Inc.

In trials of

CHRS

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

W0ZE0NT8IF

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate CancerProstate Cancer

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05177770

Updated Oct 11, 2026.